Glaxosmithkline Plc Adr Stock Analysis
| GSK Stock | USD 36.17 0.38 1.04% |
GlaxoSmithKline PLC ADR is undervalued with Real Value of 40.29 and Target Price of 45.07. The main objective of GlaxoSmithKline PLC stock analysis is to determine its intrinsic value, which is an estimate of what GlaxoSmithKline PLC ADR is worth, separate from its market price. There are two main types of GlaxoSmithKline PLC's stock analysis: fundamental analysis and technical analysis.
The GlaxoSmithKline PLC stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
GlaxoSmithKline |
GlaxoSmithKline Stock Analysis Notes
About 17.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.35. The company has Price/Earnings To Growth (PEG) ratio of 0.81. GlaxoSmithKline PLC ADR last dividend was issued on the 21st of February 2025. The entity had 1226:1000 split on the 22nd of July 2022. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States. To learn more about GlaxoSmithKline PLC ADR call Emma Walmsley at 44 20 8047 5000 or check out https://www.gsk.com.GlaxoSmithKline PLC Quarterly Total Revenue |
|
GlaxoSmithKline PLC ADR Investment Alerts
| Latest headline from gurufocus.com: DEADLINE ALERT for TIXT, MODV, GSK, MPWR Law Offices of Howard G. ... |
GlaxoSmithKline PLC ADR Upcoming and Recent Events
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GlaxoSmithKline Largest EPS Surprises
Earnings surprises can significantly impact GlaxoSmithKline PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-07-29 | 2020-06-30 | 0.64 | 0.57 | -0.07 | 10 | ||
2016-02-03 | 2015-12-31 | 0.61 | 0.69 | 0.08 | 13 | ||
1995-02-07 | 1994-12-31 | 0.9 | 0.99 | 0.09 | 10 |
GlaxoSmithKline PLC Environmental, Social, and Governance (ESG) Scores
GlaxoSmithKline PLC's ESG score is a quantitative measure that evaluates GlaxoSmithKline PLC's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of GlaxoSmithKline PLC's operations that may have significant financial implications and affect GlaxoSmithKline PLC's stock price as well as guide investors towards more socially responsible investments.
GlaxoSmithKline PLC Thematic Classifications
In addition to having GlaxoSmithKline PLC stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
GlaxoSmithKline Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eversept Partners, Llc | 2024-09-30 | 4.1 M | Equity Investment Corp | 2024-12-31 | 4 M | Arrowstreet Capital Limited Partnership | 2024-09-30 | 3.9 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-09-30 | 3.7 M | Hotchkis & Wiley Capital Management Llc | 2024-09-30 | 3.5 M | Camber Capital Management Llc | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Hsbc Holdings Plc | 2024-09-30 | 2.6 M | Renaissance Technologies Corp | 2024-09-30 | 2.3 M | Dodge & Cox | 2024-09-30 | 68.1 M | Fmr Inc | 2024-09-30 | 29 M |
GlaxoSmithKline Market Capitalization
The company currently falls under 'Large-Cap' category with a total capitalization of 73.82 B.GlaxoSmithKline Profitablity
The company has Net Profit Margin of 0.08 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.1 %, which entails that for every 100 dollars of revenue, it generated $0.1 of operating income.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.15 | 0.19 | |
| Return On Capital Employed | 0.20 | 0.37 | |
| Return On Assets | 0.10 | 0.15 | |
| Return On Equity | 0.42 | 0.47 |
Management Efficiency
GlaxoSmithKline PLC ADR has Return on Asset of 0.0693 % which means that on every $100 spent on assets, it made $0.0693 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.228 %, implying that it generated $0.228 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.19 this year. Return On Capital Employed is expected to rise to 0.37 this year. At this time, GlaxoSmithKline PLC's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 71.2 B this year, although the value of Non Current Liabilities Other will most likely fall to about 5.5 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.84 | 2.98 | |
| Tangible Book Value Per Share | (2.49) | (2.37) | |
| Enterprise Value Over EBITDA | 9.29 | 17.22 | |
| Price Book Value Ratio | 5.06 | 8.65 | |
| Enterprise Value Multiple | 9.29 | 17.22 | |
| Price Fair Value | 5.06 | 8.65 | |
| Enterprise Value | 61.1 B | 44.8 B |
Leadership at GlaxoSmithKline PLC emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 16th of February 2025, GlaxoSmithKline PLC retains the risk adjusted performance of 0.0168, and Market Risk Adjusted Performance of 0.0368. GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.GlaxoSmithKline PLC ADR Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. GlaxoSmithKline PLC middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for GlaxoSmithKline PLC ADR. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
GlaxoSmithKline PLC Outstanding Bonds
GlaxoSmithKline PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlaxoSmithKline PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlaxoSmithKline bonds can be classified according to their maturity, which is the date when GlaxoSmithKline PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US377320AA45 Corp BondUS377320AA45 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| GLAXOSMITHKLINE CAPITAL PLC Corp BondUS377373AH85 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AM97 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AN70 | View |
GlaxoSmithKline PLC Predictive Daily Indicators
GlaxoSmithKline PLC intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlaxoSmithKline PLC stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GlaxoSmithKline PLC Corporate Filings
6K | 13th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 11th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 5th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 3rd of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 28th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 27th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 21st of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 16th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
GlaxoSmithKline PLC Forecast Models
GlaxoSmithKline PLC's time-series forecasting models are one of many GlaxoSmithKline PLC's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlaxoSmithKline PLC's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About GlaxoSmithKline Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how GlaxoSmithKline PLC prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GlaxoSmithKline shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GlaxoSmithKline PLC. By using and applying GlaxoSmithKline Stock analysis, traders can create a robust methodology for identifying GlaxoSmithKline entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.23 | 0.31 | |
| Operating Profit Margin | 0.26 | 0.32 | |
| Net Profit Margin | 0.19 | 0.22 | |
| Gross Profit Margin | 0.83 | 0.79 |
Current GlaxoSmithKline Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GlaxoSmithKline analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GlaxoSmithKline analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 45.07 | Buy | 7 | Odds |
Most GlaxoSmithKline analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand GlaxoSmithKline stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of GlaxoSmithKline PLC ADR, talking to its executives and customers, or listening to GlaxoSmithKline conference calls.
GlaxoSmithKline Stock Analysis Indicators
GlaxoSmithKline PLC ADR stock analysis indicators help investors evaluate how GlaxoSmithKline PLC stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading GlaxoSmithKline PLC shares will generate the highest return on investment. By understating and applying GlaxoSmithKline PLC stock analysis, traders can identify GlaxoSmithKline PLC position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 3.4 B | |
| Total Stockholder Equity | 13.3 B | |
| Capital Lease Obligations | 1.2 B | |
| Property Plant And Equipment Net | 10 B | |
| Cash And Short Term Investments | 5 B | |
| Cash | 2.7 B | |
| 50 Day M A | 34.4858 | |
| Net Interest Income | -735 M | |
| Total Current Liabilities | 21.1 B | |
| Forward Price Earnings | 8.5543 | |
| Stock Based Compensation | 307 M | |
| Long Term Debt | 14.2 B | |
| Common Stock Shares Outstanding | 4.1 B | |
| Total Cashflows From Investing Activities | -1.6 B | |
| Tax Provision | 756 M | |
| Quarterly Earnings Growth Y O Y | 0.167 | |
| Accounts Payable | 3.7 B | |
| Net Debt | 15.3 B | |
| Other Operating Expenses | 23.6 B | |
| Non Current Assets Total | 40.4 B | |
| Liabilities And Stockholders Equity | 59 B | |
| Non Currrent Assets Other | 634 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.167 | Dividend Share 0.61 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.